BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Nov 11, 2025 • 10min
The early part of 2026 is going to be a key time for REGENXBIO's gene therapies, with an FDA decision date schedule for Hunter's Syndrome and a pivotal trial readout in DMD
CEO Curran Simpson describes REGENXBIO's expertise in AAV, and walks us through the company's programs.
Nov 11, 2025 • 9min
Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss
Founder and CEO Tien Lee describes how Aardvark's approach focuses on the gut-brain axis.
Nov 11, 2025 • 13min
Stifel's Head of Therapeutics Paul Matteis shares his take on the sector and discusses names he covers that have key catalyst events
He shares his thoughts on uniQure, Xenon, Alkermes, Compass Pathways, GH Research MindMed, and Dyne.
Nov 11, 2025 • 8min
Upstream Bio is focused on the TSLP space, and has a unique approach of targeting the receptor as opposed to the ligand. It might give them a better dosing and efficacy profile.
CEO Rand Sutherland describes TSLP pathway and Upstream's choice to hit the receptor, and how this could define the company's competitive profile.
Nov 10, 2025 • 11min
Adaptyx announced $14M in additional seed financing to fund the development of a continuous health monitoring device that aims to track small molecules, electrolytes, hormones, drugs, and proteins
Co-Founder & CEO Vijit Sabnis describes the company's goal of taking the field from continuous glucose monitoring to capturing a wider range of human biochemistry, and the clinical benefits that could flow from that.
Nov 8, 2025 • 10min
Aulos Bioscience presented phase 2 data at SITC for its antibody that binds to IL-2 and prevents CD25 binding - showing responses in melanoma and lung
CEO Aron Knickerbocker walks us through the data and describes why he believes imneskibart's ability to show a higher Teff/Treg ratio in patients, and how it correlates with longer time on treatment and overall survival, may be unique in the IL-2 class.
Nov 8, 2025 • 9min
Enara Bio publicly announced its first cancer specific 'dark genome antigen' target at SITC - DARKFOX, an alternative open reading frame associated with FOXM1
CEO Kevin Pojasek describes the past challenge of drugging FOXM1, and why he believes DARKFOX will be an ideal target for the company's T-cell engager platform.
Nov 8, 2025 • 12min
Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs
The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.
Nov 8, 2025 • 13min
Synthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC
Co-Founder & CEO Debanjan Ray walks us through learnigs the IL-2 space has seen over the years, and describes why Synthekine is targeting both the α and β receptors in this case. In addition to the phase 1a/1b that is reading at SITC, Synthekine has already started a randomized phase 2 study.
Nov 8, 2025 • 9min
Marengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types
CEO Zhen Su walks us through the data, which had 46 efficacy-evaluable patients and showed a 20% ORR and 80% DCR across multiple tumor types.
